CClinicalTrials.gg
CompletedNCT03857126SURFAO-ObstUpdated Jun 4, 2021

Computer-assisted Fetal Monitoring - Obstetrics

An observational study in ECG-PCG-CTG Acquisition on Pregnant Voluntary Subjects, sponsored by University Hospital, Grenoble. Completed at 1 site in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-04.

Sponsored by University Hospital, Grenoble · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
Female
01

Study summary

In the context of fetal heart monitoring, the SurFAO project offers an alternative to current clinical routines. The challenge is to extract, from few non-invasive sensors on the maternal abdomen, a fetal electrocardiogram (ECGf) of great quality allowing a clinical diagnosis (follow-up of the FHR (fetal heart rate)) and extraction of ECG waveforms).

The proposed approach proposes a technological breakthrough shared by a consortium of researchers and clinicians. The originality is driven by innovative methodological choices: the use of a multimodal system (ECG coupling with PCG (phonocardiographic)) for the signal acquisition in order to increase the robustness of information extraction, by taking into account clinical uses and the need for the monitoring process support, and by setting up a reference for this multimodal database.

The objective is to feed a database that will be used in the future to develop ECGf extraction methods estimating the FHR.

Read the detailed description

To monitor the well-being of a fetus or for a clinical diagnosis, a challenge is to extract a fetal electrocardiogram (fECG) signal of high quality from a limited number of non-invasive sensors on the maternal abdomen.

During childbirth, fetal monitoring is assessed by the fetal heart rate (FHR), classically from cardiotocography (CTG). The aim is to monitor FHR variability anomalies that reflect a too high fetal malaise. It is very common to have difficulties to reliably record FHR due to confusion of rhythms of the mother and the fetus that can lead to unnecessary caesareans. With 800000 childbirths in France per year, improving the reliability of FHR estimation by fECG analysis is therefore of high clinicalinterest.

To deal with, the proposed approach aims at coupling two complementary cardiac information acquired at the best-located position. Therefore, the proposed solution is (i) to combine the use of electrophysiological sensors ECG and acoustic sensors of microphonic type that can register phonocardiographic signals (PCG), (ii) to assist by computer the clinical expertise to choose the best sensors location. Several methodological aspects will be considered: to improve the robustness of the FHR estimation with degraded signals based on multimodality, to overcome some practical limitations to extract the fECG waveforms by enhancing the process extraction with PCG and to assist the user in the sensors choice and placement by predicting their best locations and their kinds (ECG or PCG).

The SurFAO project proposes then an original approach of computer-assisted fetal monitoring and thus differs from previous published works of fECG extraction solutions, only based on algorithmic performances mostly in well-controlled situations. The original aspects of the investigator's proposal are the innovative methodological choices based on multimodality and informed recording process, the consideration of the medical uses and of the necessity to help the clinical monitoring to design the algorithms, the new reference multimodal database, and the academic-clinical consortium, that will guarantee the relevance of all proposed parts.

02

Conditions studied

  • ECG-PCG-CTG Acquisition on Pregnant Voluntary Subjects

Keywords

  • Signal Database
  • Pregnancy
  • Electrocardiogram
  • Phonocardiogram
  • Cardiotocography
  • Usability
03

In context

Lead sponsor

University Hospital, Grenoble is the lead sponsor of 815 studies on the registry; 205 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Pregnant women

Inclusion criteria

  • Pregnant of a single pregnancy,
  • Aged over 18,
  • During the 9th month of pregnancy (>= 37 weeks),
  • With uncomplicated maternal and fetal pregnancy follow-up,
  • With a BMI between 18.5 and 30 at the beginning of pregnancy,
  • Without a notable medical history,
  • Enrolled in a social security scheme,
  • Having signed the consent form for the study.

Exclusion criteria

Exclusion Criteria:

  • Subject under guardianship, protected by law or deprived of liberty (Article L1121-8),
  • Subject under administrative or judicial supervision,
  • Subject in exclusion period of another study,
  • With toxic consumption (i.e. tobacco, alcohol, cannabis),
  • With inaccurate pregnancy term,
  • With denial of pregnancy.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (actual)
Patient registry
No

Groups and cohorts

  • Pregnancy volunteer subjects

    Subjects who will agree to participate in the investigator's study will be pregnant healthy subjects with no particular antecedent, followed at the University Hospital of Grenoble for a physiological pregnancy; their child will be not affected by any prenatal pathology. Subjects will be enrolled in a 30 min monitoring phase to collect signals from ECG-PCG-CTG abdominal and thoracic non invasive sensors.

    Other: Signal acquisition

Interventions

  • OtherSignal acquisition

    ECG-PCG-CTG synchronized signals acquisition over a monitoring phase of 30 minutes. These signals will be acquired with passive non invasive sensors (abdominal and thoracic).

    Also known as: Non invasive ECG-PCG-CTG sensors

06

What researchers measure

Primary outcomes

  1. ECG Signals Database

    Synchronized signals from ECG electrodes during a 30-minute monitoring phase. Tracking of the electrical activity in the heart. During the study period we will collect R wave, P wave, QT interval, ST interval, QRS complex, RR interval components of the ECG. Signals were then processed to extract fetal ECG.

    Time frame: 30 minutes

  2. PCG Signals Database

    Synchronized signals from PCG sensors during a 30-minute monitoring phase. Acquisition of acoustic information reflecting the contraction and relaxation of the heart. During the study period we will collect S1 and S2 sounds components of the PCG. Signals were then processed to extract fetal PCG.

    Time frame: 30 minutes

  3. CTG Signals Database

    CTG is continuous monitoring of the fetal heart rate (gold standard reference). Physicians evaluate specific clinical CTG parameters by means of visual inspection.

    Time frame: 30 minutes

Secondary outcomes

  1. Subject Acceptability: Score

    The subject acceptability score will be composed by the addition of 7 scales. These scales have been specifically created for the SurFAO system. The score can go from 0 (worst) to 70 (best). Each scale can give from 0 to 10 points to the final score.

    Time frame: 15 minutes

  2. Subject Acceptability : Descriptive analysis

    Open questions will be asked to the subjects in a questionnaire. A descriptive analysis will be done with the answers.

    Time frame: 15 minutes

  3. Use Error evaluation : System Usability Scale (SUS)

    The System Usability Scale (SUS) is a validated tool for assessing the subjective usability of a system, in this case, the SurFAO System. It contains 10 questions that are rated on a scale from 1 to 5. "The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100." Jeff Sauro established the average score of SUS is 68. The score can go from 0 (worst) to 100 (best).

    Time frame: 15 minutes

  4. Use Error evaluation : Descriptive analysis

    In a journal, the users will write their difficulties using the system. A descriptive analysis will be done with the answers.

    Time frame: 15 minutes

07

Study locations

1 site
  • University Hospital Grenoble
    Grenoble, 38043, France
08

References and documents

Publications

  • Equy V, Buisson S, Heinen M, Schaal J-P, Hoffmann P, Sergent F. Confusion between maternal and fetal heart rate during delivery: risk factors and consequences British Journal of Midwifery, vol.20 (11), 2012
  • Gobillot S, Fontecave-Jallon J, Equy V, Rivet B, Gumery PY, Hoffmann P. Non-invasive fetal monitoring using electrocardiography and phonocardiography: A preliminary study. J Gynecol Obstet Hum Reprod. 2018 Nov;47(9):455-459. doi: 10.1016/j.jogoh.2018.08.009. Epub 2018 Aug 23. PubMed 30144558 ↗
  • Noorzadeh S, Rivet B, Gumery PY. An application of Gaussian processes on ocular artifact removal from EEG. Annu Int Conf IEEE Eng Med Biol Soc. 2015 Aug;2015:554-7. doi: 10.1109/EMBC.2015.7318422. PubMed 26736322 ↗
  • Noorzadeh S, Niknazar M, Rivet B, Fontecave-Jallon J, Gumery PY, Jutten C. Modeling quasi-periodic signals by a non-parametric model: application on fetal ECG extraction. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:1889-92. doi: 10.1109/EMBC.2014.6943979. PubMed 25570347 ↗
  • Noorzadeh S, Rivet B, Guméry PY. A multi-modal approach using a non-parametric model to extract fetal ECG. Proc. IEEE Int. Conf. Acoustics, Speech, and Signal Processing (ICASSP), Brisbane, Australia, 2015, pp. 1856-60

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03857126
Lead sponsor
University Hospital, Grenoble
Collaborators
TIMC-IMAG, University Grenoble Alps, Clinical Investigation Centre for Innovative Technology Network
Responsible party
Sponsor
First posted
Feb 27, 2019
Start date
May 2, 2019
Primary completion
Apr 15, 2021
Completion
May 31, 2021
Last update
Jun 4, 2021

Study contacts

Véronique Equy
principal investigator · CHU Grenoble Alpes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion